Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERELI phase II study of pemigatinib and retifanlimab in advanced dedifferentiated liposarcoma
2022-501993-21-00Phase 2Authorised
- Sponsor
- Region Skåne
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of pemigatinib and retifanlimab in dedifferentiated liposarcoma (DDL), sponsored by Region Skåne. Primary endpoint: Progression-free survival at 24 weeks. Planned start Oct 2023; status: authorised.
02
Drugs
pemigatinibretifanlimab
03
Conditions
dedifferentiated liposarcoma (DDL)
Beyond the preview
Go deeper on 2022-501993-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501993-21-00.